Change in substantial holding

Aug 17, 2026 at 2:52 AM EDT · Issued by Radiopharm Theranostics Limited via ASX

Filed with ASX · Aug 17, 2026 at 2:52 AM EDT

On 6ix: 6ix.com/news/change-in-substantial-holding-786

To Company Name/Scheme ACN/ARSN 1. Details of substantial holder (1) Name ACN/ARSN (if applicable) - 13/08/2026 The previous notice was given to the company on 30/07/2026 The previous notice was dated 28/07/2026 2. Previous and present voting power *The % substantial is based on...

View Attachment

6ix hasn’t read this filing yet.

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

RAD to meet with US FDA to align on RAD 101 Phase 3 TrialAug 16
Notice of Extraordinary General Meeting and Proxy FormAug 12
Share Purchase Plan - Now OpenAug 6
Update - Proposed issue of securities - RADAug 4
Application for quotation of securities - RADAug 2

Later from Radiopharm Theranostics

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain MetastasesAug 17
RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT TrialAug 19
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialAug 20
Ceasing to be a substantial holderAug 24
RAD Doses First Patient in Second Cohort of BetaBart (RV-01)Aug 25

All Radiopharm Theranostics news releases